Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?Zacks Investment Research • 07/27/26
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 07/22/26
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market TodayZacks Investment Research • 07/20/26
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics PharmaceuticalsThe Motley Fool • 07/14/26
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 07/13/26
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?The Motley Fool • 07/13/26
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology PowerhouseMarketBeat • 07/11/26
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.The Motley Fool • 07/08/26
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.The Motley Fool • 07/08/26
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 07/07/26
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics BuyoutZacks Investment Research • 07/07/26
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)Newsfile Corp • 07/07/26